| Name | INCB 3284 |
| Description | INCB 3284 is an orally available, selective and high affinity chemokine receptor 2 (CCR2) antagonist that inhibits monocyte chemotactic protein 1 from interacting with hCCR2.INCB 3284 is used in the study of hemorrhagic shock. |
| In vitro | INCB3284 exhibited an IC50 of 3.7 nM for antagonizing the binding of monocyte chemoattractant protein-1 to hCCR2, an IC50 of 4.7 nM for antagonizing chemotactic activity, and an IC50 of 84 μM for inhibiting hERG potassium currents[1]. |
| In vivo | INCB 3284 (1 mg/kg/day, intraperitoneal injection) or C021 significantly improved the neurological outcomes in AOM-treated mice, reduced microglial activation, decreased phosphorylation of ERK1/2, and attenuated the upregulation of cytokines induced by AOM[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.84 mM), Sonication is recommended.
H2O : < 0.1 mg/mL (insoluble)
DMSO : 60 mg/mL (115.26 mM), Sonication is recommended.
|
| Keywords | MCP-1-hCCR2 | INCB-3284 | INCB3284 | INCB 3284 | CCR2 |
| Inhibitors Related | AZD2098 | MLN-3897 TFA | Artemotil | CCR2 antagonist 5 | INCB-9471 | Maraviroc | BMS-817399 | Ancriviroc | Pirfenidone | Vercirnon | PNU-177864 | CCR6 antagonist 1 |
| Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Chemokine Inhibitor Library | Inhibitor Library | Orally Active Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
